Generic Revuforj Availability
Last updated on Aug 6, 2025.
Revuforj is a brand name of revumenib, approved by the FDA in the following formulation(s):
REVUFORJ (revumenib citrate - tablet;oral)
-
Manufacturer: SYNDAX
Approval date: November 15, 2024
Strength(s): EQ 25MG BASE [RLD], EQ 110MG BASE [RLD], EQ 160MG BASE [RLD]
Is there a generic version of Revuforj available?
No. There is currently no therapeutically equivalent version of Revuforj available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Revuforj. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Inhibitors of the menin-MLL interaction
Patent 10,683,302
Issued: June 16, 2020
Inventor(s): Cacatian; Salvacion et al.
Assignee(s): VITAE PHARMACEUTICALS, LLC (Madison, NJ)The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Patent expiration dates:
- June 8, 2037✓✓
- June 8, 2037
-
Inhibitors of the menin-MLL interaction
Patent 11,479,557
Issued: October 25, 2022
Inventor(s): Cacatian; Salvacion et al.
Assignee(s): VITAE PHARMACEUTICALS, LLC (Madison, NJ)The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Patent expiration dates:
- June 8, 2037✓✓
- June 8, 2037
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 15, 2029 - NEW CHEMICAL ENTITY
- November 15, 2031 - TREATMENT OF RELAPSED OR REFRACTORY MIXED-PHENOTYPE ACUTE LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER.
- November 15, 2031 - TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
- November 15, 2031 - TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOCYTIC LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
More about Revuforj (revumenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
